BBIO vs PFE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PFE is the larger of the two ($156.92B market cap): the incumbent the market prices for continued execution (9.32x forward earnings, beta 0.30). BBIO is the smaller challenger ($15.03B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, BBIO fits: analysts expect its revenue to rise 52% next year, against a 4% decline for PFE. If you believe in profit, PFE fits: it is expected to make money next year (9.32x forward earnings), while BBIO is still expected to post a loss.
BBIO vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BBIO | PFE | What it tells you |
|---|---|---|---|
| Market cap | $15.03B | $156.92B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -282.25 | 9.32 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.94 | 0.30 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 47% of range | 50% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how BBIO and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BBIO and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BBIO and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does BridgeBio Pharma (BBIO) do?
BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
BBIO vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BBIO drivers: Attruby (acoramidis) commercial ramp; Pipeline diversification and 2026 filings.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
BBIO or PFE: which should you pick?
If the story you believe is BBIO's (Attruby (acoramidis) commercial ramp), BBIO is the more direct way to own it; if it is PFE's (Oncology expansion via Seagen), PFE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BBIO and PFE guides.
BBIO vs PFE: the full fundamentals
BBIO. BBIO trades at about 16 times trailing revenue, a multiple that rests on continued Attruby growth and pipeline launches, since the company still loses money. Third-quarter revenue nearly tripled year over year and the loss per share beat estimates for the first time in four quarters, and the shares are roughly flat in 2026 after a 13% rise over the past month. The 20 analysts tracked by Yahoo Finance hold an average target near $107, above the November 20 close of about $77, with the BBP-418 FDA decision due by November 27.
PFE. At about $27.54 (November 20, 2026) Pfizer trades at about 9x forward earnings with a dividend yield near 6.3%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges, including a GAAP loss in Q2 2026, rather than weak operations. After pulling back from its early-November high the stock sits below the 26 analysts' mean target of about $30.22 (an average buy rating), so the valuation balances substantial cash generation against flat-to-lower consensus earnings.
Headline figures (approximate, November 2026): BBIO shows revenue (ttm) ~$946M, revenue (q3 2026) ~$353M, up ~193% year over year, q3 2026 eps vs estimate ~-$0.42 vs ~-$0.56, net income (ttm) ~-$592M; PFE shows revenue (ttm) ~$63.6 billion (Q3 2026 ~flat YoY), operating margin ~29%, net income (ttm, gaap) ~$4.0 billion, q3 2026 adjusted eps ~$0.87 vs ~$0.74 consensus.
The bottom line: BBIO vs PFE
BBIO and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BBIO and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how BBIO or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about BridgeBio Pharma
Ask Walnut's AI anything about BBIO and see how it fits what you own.
FAQ
What is the difference between BBIO and PFE?
+
BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BBIO or PFE the better stock?
+
Neither is universally better. PFE is the larger incumbent; BBIO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BBIO or PFE?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BBIO and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BBIO vs PFE?
+
BBIO: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. Pfizer's entrenched tafamidis franchise and Alnylam's vutrisiran (Amvuttra) are well-funded rivals fighting for the same patients. Any FDA delay, rejection, request for more data, or narrower-than-expected label for BBP-418 (decision due by November 27, 2026), infigratinib, or encaleret would push out the diversification timeline. The company is still unprofitable, with a trailing net loss near $592 million and roughly $3.38 billion of debt, and although the third-quarter loss beat estimates, the three quarters before it came in wider than expected. Pricing pressure, slower diagnosis growth, or a valuation that still embeds heavy optimism (about 16 times trailing sales) could all weigh on the shares. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of November 2026 has revenue of about $63.1 billion in 2026 slipping to $60.8 billion in 2027, with EPS of roughly $3.05 and $2.95, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.4 billion against $14.3 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout near 246% of trailing GAAP EPS of about $0.70), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BBIO or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.